Clinical Trial Update: Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients [Phase 1]

View source ↗

Summary

A Phase 1 dose-ranging study evaluating the safety, PK, and initial antiviral efficacy of the investigational HBV agent NVR-3-778 in patients with chronic hepat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• NVR 3-778

Snippet

Sponsor: Novira Therapeutics, Inc. | Conditions: Chronic Hepatitis B | Phase 1 | Status: COMPLETED